Behçet disease (BD) is a chronic relapsing systemic vasculitic disorder affecting the arteries, veins, and vessels of any size. Vascular lesions in BD usually represent an occlusive nature suggesting a hypercoagulable/ prothrombotic state. Coronary arteries are rarely involved in BD. In this report, a 27-year-old male patient in whom myocardial infarction developed secondary to coronary arter-ial thrombosis together with deep venous thrombosis was presented. This is a review of the pathologic hemostasis and the prothrombotic state of BD.
Vascular involvement is a frequent and potentially life-threatening manifestation of Behçet's disease (BD). The vasculopathy of BD can involve both arteries and veins of any size and represents an occlusive character (1) . However, coronary involvement is very rare in BD. In this paper, a young BD patient in whom myocardial infarction developed secondary to coronary arterial occlusion is presented. The patient is of interest for the presence of hypercoagulability because he also had venous thrombosis. The aim of this report is to review coronary involvement in BD, to outline the complicated pathologic hemostasis of BD, and to shed light on the underlying mechanisms leading to hypercoagulability in BD.
CASE REPORT
A 27-year-old male was admitted to our hospital with the complaints of retrosternal prolonged chest pain radiating to the left shoulder. He had first developed recurrent oral ulcerations and large acneiform cutaneous lesions 7 years earlier. Five years later, he had blurred vision. The diagnosis of uveitis was made and was treated locally. Despite this local therapy, his ocular and mucocutaneous symptoms recurred. In February 2001, he suffered from sudden severe retrosternal pain that was radiating to his left shoulder, and he was admitted to a private center. He was diagnosed as having myocardial infarction with ST segment elevation in leads V1 to V5 on electrocardiography (ECG) and elevated serial cardiac enzymes. Aspirin and heparin infusion were started. However, he refused further diagnostic procedure because of economical reasons and was admitted to our hospital the day after. The ECG and cardiac enzyme levels of the patient were compatible with anterior subacute myocardial infarction. He had no history of hypertension, hyperlipidemia, or diabetes mellitus; moreover, he was neither a smoker nor overweight. His family history was unremarkable. On physical examination, two aphthous ulcerations were present on the buccal mucosa and multiple follicular lesions were present over the shoulders. Homans test was positive on the right lower extremity.
Laboratory evaluation showed elevated erythrocyte sedimentation rate (ESR) (38 mm/ hour) and positive C-reactive protein (CRP). Urinanalysis and serum biochemistry were within normal limits. Ophthalmologic examination revealed keratic precipitates on corneal endothelium possibly due to previous uveitis attacks. Coronary angiography demonstrated total occlusion of the left anterior descending (LAD) coronary artery and patent circumflex and right coronary arteries ( Fig. 1 ). Pulmonary tomography was normal. Testing for causes of hypercoagulability including antinuclear antibody, anticardiolipin antibodies, lupus anticoagulant, protein C and S deficiency, antithrombin III deficiency, and activated protein C resistance yielded negative results. Venous Doppler ultrasonography of the right lower extremity revealed thrombus in the right popliteal vein. The patient was diagnosed as having Behçet's disease complicated with deep venous thrombosis and myocardial infarction, and was treated with low-molecular-weight heparin enoxaparin 40 mg twice daily, aspirin 300 mg every day, metoprolol 25 mg twice daily, enalapril 2.5 mg twice daily, colchicine 0.5 mg thrice daily, intramuscular benzathine penicilline 1.2 million units every 3 weeks, and interferon-α 5 million units three times a week. His clinical condition improved with the therapy and the chest pain resolved with no additional symptoms. ESR, CRP, and cardiac enzymes decreased to normal limits. One month after his discharge, the patient was completely asymptomatic and laboratory parameters were unremarkable. In his last visit in April 2004, no further vascular or ocular symptoms had developed and he is being observed at 6-month intervals.
DISCUSSION
Behçet disease was initially described by Hulusi Behçet, a Turkish dermatologist by the triple complex of relapsing oral and genital ulcerations and chronic iridocyclitis with hypopyon in 1937 (2). The clinical spectrum of the disease is far from this original description. Although International Study Group Criteria for BD includes mucocutaneous and ocular findings (3), BD is actually a vasculitic systemic disorder with a clinical spectrum including cardiovascular, pulmonary, gastrointestinal, urogenital, neurologic, and musculoskeletal manifestations. Vascular involvement in BD has unique properties among other vasculitides so that it can involve arteries, veins, and vessels of all sizes. However, coronary involvement in BD is extremely rare and reported anecdotally in the English literature (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . In our series of 137 patients with BD, 38 had vascular manifestations, but none of those patients had coronary involvement (15) . In another report, there were only five cases of myocardial involvement among 200 patients with BD (4). Three cases of coronary arterial thrombosis were detected in an autopsy study of 170 Japanese patients with BD with no information regarding the cause of death of the patients (5) . Myocardial infarction developed in the majority of those patients at a young age. Moreover, there was no obvious risk factor for coronary heart disease other than smoking in two patients (6) , and reduced plasminogen activator resulting in impaired blood fibrinolysis in one patient (7) . We herein presented an additional patient in whom myocardial infarction developed at a young age without any cardiovascular risk factors, a detailed search for a hereditary thrombophilic factor yielded negative results.
This young patient is also of interest because both myocardial infarction and deep venous thrombosis were present during his clinical course. The development of pathologic thromboses in both venous and arterial vasculature is a unique clinical manifestation of BD among other vasculitides. Several inherited risk factors associated with thrombophilia may contribute to the prothrombotic state of BD (16, 17) . On the other hand, there is evidence for the universal activation of the coagulation pathway in BD. We have previously demonstrated elevated concentrations of thrombin-antithrombin III complex (TAT) and prothrombin fragment 1+2 (PF 1.2) in clinically "thrombosis-free" patients with BD, which reflect intravascular excessive thrombin formation (18, 19) . Moreover, impaired fibrinolytic kinetics with compensatory activation to the hypercoagulable state is present in BD (18) (19) (20) . The recently identified vitamin K-dependent anticoagulant protein Z was lower in our group of BD patients compared to healthy controls. Moreover, there was a positive correlation between the disease duration and protein Z levels, which might reflect the diminution of the disease activity with the passage of time (21) . We have also demonstrated defective secretion of tissue factor pathway inhibitor (TFPI), which is the key anticoagulant modulating tissue factor (TF)-dependent pathway of coagulation, from endothelial cells in response to LMWH challenge in BD patients (22) . Because the TF is the initial step of the coagulation cascade, the defective TFPI reserve in Behçet's endothelium may be regarded as important evidence of the prothrombotic state of BD.
There are also clues of endothelial cell injury and/or pathologic activation in BD. An endothelial product, von Willebrand factor, and soluble thrombomodulin concentration, an endothelial injury marker, were found to be elevated in active BD patients (23) (24) (25) . Diminished endothelial TFPI pool in BD reflects vascular injury (22) . We have recently demonstrated that circulating E-selectin, which is expressed by activated endothelial cells, was increased in BD patients compared to controls (26) . Arachidonic acid metabolites released from endothelium and platelets are also involved in pathologic hemostasis and thrombotic tendency in BD. We reported high thromboxane B 2 (TXB 2 ) and 6-keto prostoglandin F 1α levels in the prothrombotic state of BD, representing activation of both proaggregant and protective antiaggregant pathways, respectively (27) . Moreover, we confirmed in a dynamic study with desmopressin that in the patients with Behçet's disease basal thrombomodulin concentrations are increased and could not be provoked further by desmopressin infusion, and that both TXB 2 and PGF 1α increments occur concurrently (17) . In summary, defective regulation of coagulation, impaired fibrinolytic kinetics, and endothelial cell injury and resultant endothelial loss and/or dysfunction/hyperfunction may contribute to the prothrombotic state of BD (28) (Fig. 2) .
Current data regarding the treatment thrombotic disease in BD are not clear. In patients with severe vasculitis, immunosuppresive therapy is usually the recommended practice. Combination of the corticosteroids and cytotoxic agents is usually used for this purpose (29, 30) . However, because of the limitations and toxicity of cytotoxic therapies, alternative regimens should be developed. Likewise, management of the coronary involvement in BD is challenging. Although invasive therapeutic procedures could be beneficial, some authors prefer noninvasive treatment regi-mens, including immunosuppressive drugs (4, 6, (11) (12) (13) . Moreover, stent re-occlusion could further complicate the problem (11) . Interferon-α is an antiviral agent with immunomodulatory properties. It has been shown to be effective in BD patients with mucocutaneous, musculoskeletal, and eye involvement (31) . We have recently demonstrated that interferon-α therapy is also efficacious in patients with BD complicated by vascular involvement who were previously unsuccessfully treated with steroids and/or immunosuppressive agents (32) . Therefore interferon-α therapy was preferred in this case. After a 4-year follow-up period, he is asymptomatic regarding cardiac and ocular systems, his physical examination is normal, and laboratory tests, including cardiac enzymes, are within normal limits.
In conclusion, BD represents a hypercoagulable/prothrombotic state, and should be considered in the differential diagnosis of myocardial infarction in the young. Interferon-α therapy could be an effective alternative to toxic immunosuppressive treatment modalities in patients with BD complicated by vascular thrombosis.
